Table 1 Baseline characteristics of all enroled patients (N = 48)

From: Neoadjuvant serplulimab combined with chemotherapy for resectable oesophageal squamous cell carcinoma: a single-arm, phase 2 trial

Variables

 

Age (years), n (%)

 <65

23 (47.9%)

 ≥65

25 (52.1%)

 Mean (standard deviation)

64.5 (6.3)

BMI (kg/m2), mean (standard deviation)

21.3 (2.9)

ECOG performance status, n (%)

 

 0

37 (77.1%)

 1

11 (22.9%)

Smoking history, n (%)

 

 Former or current

35 (72.9%)

 Never

13 (27.1%)

Alcohol-drinking history, n (%)

 

 Former or current

31 (64.6%)

 Never

17 (35.4%)

Pulmonary function, mean (standard deviation)

 

 FEV1 (L)

2.6 (0.6)

Tumour location, n (%)

 

 Upper

5 (10.4%)

 Middle

25 (52.1%)

 Lower

18 (37.5%)

T stage, n (%)

 

 T2

2 (4.2%)

 T3

46 (95.8%)

N stage, n (%)

 

 N0

27 (56.3%)

 N1

15 (31.3%)

 N2

4 (8.3%)

 N3

2 (4.2%)

Clinical stage, n (%)

 

 Ⅱ

27 (56.3%)

 Ⅲ

19 (39.6%)

 ⅣA

2 (4.2%)

  1. BMI body mass index, ECOG Eastern Cooperative Oncology Group, FEV1 forced expiratory volume in 1 s.